• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

23Andme Holding Co. (NQ: ME )

4.650 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about 23Andme Holding Co.

< Previous 1 2 3 Next >
23andMe Regains Compliance With Nasdaq Listing Requirements
October 30, 2024
From 23andMe, Inc.
Via GlobeNewswire
23andMe Appoints Three New Independent Directors to Board
October 29, 2024
From 23andMe, Inc.
Via GlobeNewswire
23andMe Introduces New Feature Helping African Americans Trace Their Roots to Post Slavery Communities in the South
October 17, 2024
The new African American Genetic Groups feature traces customers' ancestral connections from before the early-to-mid-20th century migrations to more than 200 communities in Southern states 
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces Completion of 1-for-20 Reverse Stock Split
October 16, 2024
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces 1-for-20 Reverse Stock Split
October 11, 2024
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces Mathew Knowles as New Brand Ambassador
October 08, 2024
Collaboration to help increase awareness of the power of genetic testing when it comes to learning about personal health risks 
From 23andMe, Inc.
Via GlobeNewswire
23andMe Launches New Genetic Report on Likelihood of Frequent Emotional Eating
September 25, 2024
Provides 23andMe+ Premium members with insight into their likelihood of experiencing emotional eating based on their genetics 
From 23andMe, Inc.
Via GlobeNewswire
Independent Directors of 23andMe Resign from Board
September 17, 2024
From 23andMe, Inc.
Via GlobeNewswire
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
September 15, 2024
From 23andMe, Inc.
Via GlobeNewswire
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
September 15, 2024
From 23andMe, Inc.
Via GlobeNewswire
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
September 12, 2024
23andMe, National Human Genome Research Institute, and Johns Hopkins University conducted collaborative research that studied sickle cell trait in a diverse population 
From 23andMe, Inc.
Via GlobeNewswire
23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024
September 03, 2024
From 23andMe, Inc.
Via GlobeNewswire
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
August 28, 2024
In conjunction with this new offering, 23andMe, Lemonaid Health’s parent company, recently launched study focused on the role genetics may play in effectiveness and side effects of GLP-1s 
From 23andMe, Inc.
Via GlobeNewswire
23andMe Reports First Quarter Fiscal 2025 Financial Results
August 08, 2024
From 23andMe, Inc.
Via GlobeNewswire
23andMe Special Committee responds to CEO’s take-private proposal
August 02, 2024
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces CEO’s Take-Private Proposal
August 01, 2024
From 23andMe, Inc.
Via GlobeNewswire
23andMe to Report Q1 FY2025 Financial Results
July 25, 2024
From 23andMe, Inc.
Via GlobeNewswire
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
July 25, 2024
Study aims to build a comprehensive, open-source database of heritable genetics and patient-reported data in lung cancer 
From 23andMe, Inc.
Via GlobeNewswire
23ANDME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates 23andMe Holding Co. - ME
July 19, 2024
From Kahn Swick & Foti, LLC
Via Business Wire
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
June 28, 2024
From 23andMe, Inc.
Via GlobeNewswire
23andMe Launches New Genetic Report on Bipolar Disorder
June 05, 2024
Provides 23andMe+ Premium members with insight into their likelihood of developing the serious mental health illness based on thousands of genetic variants 
From 23andMe, Inc.
Via GlobeNewswire
23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
June 04, 2024
Study aims to fill research gap and empower people through access to information about their health 
From 23andMe, Inc.
Via GlobeNewswire
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
June 03, 2024
From 23andMe, Inc.
Via GlobeNewswire
Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history
May 29, 2024
Findings from 23andMe research on Parkinson’s disease published in Brain 
From 23andMe, Inc.
Via GlobeNewswire
23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
May 23, 2024
From 23andMe, Inc.
Via GlobeNewswire
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
May 14, 2024
Lemonaid Health will offer customers more affordable access to fast-acting branded ED medication that works as quickly as 15 minutes prior to sexual activity 
From 23andMe, Inc.
Via GlobeNewswire
23andMe to Report Q4 and Full Year FY2024 Financial Results
May 09, 2024
From 23andMe, Inc.
Via GlobeNewswire
Potter Handy Law Firm Represents Nearly 5,000 Clients in 23andMe Data Breach Case
April 30, 2024
From Potter Handy LLP
Via Business Wire
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
Data from neuroendocrine and ovarian cancer patient cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented 
From 23andMe, Inc.
Via GlobeNewswire
23andMe announces CEO’s intention to pursue a potential take-private
April 18, 2024
From 23andMe, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap